Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MA.21 Adjuvant Chemotherapy Trial in Breast Cancer
NCT00014222Phase 3Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Dec 2000
- Primary completion
- Feb 2014
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of epirubicin, cyclophosphamide, paclitaxel, filgrastim and epoetin alfa in breast cancer (3 arms), sponsored by Canadian Cancer Trials Group. Primary endpoint: Disease Free Survival at 13 years. Started Dec 2000; status: completed.
02
Drugs
epirubicincyclophosphamidepaclitaxelfilgrastimepoetin alfa
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00014222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00014222.